Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 594

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 594
---
 presents the changes in the fair value of the Level 2 warrant liabilities:

|                                                 |     | Private   
 Placement |         |
|:------------------------------------------------|:----|:----------|--------:|
| Fair value as of December 31, 2022              |     | $         | 179,000 |
| Change in valuation inputs or other assumptions |     |           | 268,500 |
| Fair value as of December 31, 2023              |     | $         | 447,500 |

____________ (1)Changes in valuation inputs or other assumptions are recognized in the change in fair value of warrant liabilities in the statements of operations. NOTE 13. SUBSEQUENT EVENTS The Company evaluated events that have occurred after the balance sheet date up through the date the financial statements was issued. Based upon the review, management did not identify, other than what has already been disclosed as part of the financial statement footnotes including the below, any subsequent events that would have required adjustment or disclosure in the financial statements. Sponsor Alliance On March 21, 2024, in connection with the transfer by Templar LLC (the “Sponsor”) of 800,000 Class A ordinary shares of APX Acquisition Corp. I (the “Company”) to the Sponsor’s wholly owned subsidiary, Templar Subco LLC (“Sponsor Subco”), Sponsor Subco entered into a joinder agreement with the Company (the “Joinder Agreement”) to become a party to the Letter Agreement and the Registration Rights Agreement, both dated December 6, 2021 and entered into in connection with the Company’s initial public offering. Business Combination On March 25, 2024, the Company, OmnigenicsAI Corp (“OmnigenicsAI”), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd (“MultiplAI”), a UK -basedAI -enabledpreventive medicine company, entered into a definitive Business Combination Agreement (“BCA”) that, upon closing, would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid -year, subject to the approval of APx’s shareholders and other customary closing conditions and, upon closing, OmnigenicsAI’s shares are expected to be listed on Nasdaq under the ticker symbol “OMNI”. The strategic combination creates a global AI -drivengenomic Company, focused on proving secure, precise, and reliable biological data.

F-89 APX ACQUISITION CORP. I
NOT